Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Seeks Public Feedback on New Drug Benefit-Risk Assessment Guidelines

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Releases Draft Guidelines on New Drug Benefit-Risk Assessment

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery

Fineline Cube Nov 9, 2022

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...

Policy / Regulatory

CDE Releases Guidelines on Pediatric Anti-tumor Drug Development

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released a Technical Guidelines document focused on “Clinical...

Company Deals

Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...

Company Deals

Pfizer China Partners with Alibaba Health for Disease Education at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership...

Company Deals

Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500

Fineline Cube Nov 9, 2022

China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Drug

MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial

Fineline Cube Nov 9, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...

Company Drug

Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan

Fineline Cube Nov 9, 2022

China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...

Company Deals

Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs

Fineline Cube Nov 9, 2022

Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB...

Company Deals

Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants

Fineline Cube Nov 9, 2022

China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused...

Company Drug

Cyramza Prescribed in China for Advanced Gastric Cancer

Fineline Cube Nov 9, 2022

Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...

Company Deals

Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization

Fineline Cube Nov 9, 2022

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...

Company Drug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

Fineline Cube Nov 9, 2022

US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...

Company Deals

Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...

Company Deals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

Fineline Cube Nov 8, 2022

Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD...

Posts pagination

1 … 647 648 649 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.